Newsroom | 90857 results

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2025. “We continue to make meaningful progress in our ADI-001 autoimmune Phase 1 clinical program. Site activation is progressing well with more than 20 sites currently open for...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “The recent expansion of our T...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. “The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took m...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel’s potential to be a life-changing therapy for mu...

TAMPERE, Finnland--(BUSINESS WIRE)--Im Rahmen von Forschungsarbeiten an historischer DNA, die das Museumszentrum Vapriikki in Tampere, Finnland, in Zusammenarbeit mit den Universitäten von Turku und Helsinki durchführte, konnten neue Erkenntnisse in Bezug auf Verwandtschaftsbeziehungen, Gesundheit und Fortbestand der Bevölkerung im Finnland des Mittelalters und der frühen Neuzeit gewonnen werden. Die in der Fachzeitschrift mit Peer-Review iScience veröffentlichten Forschungsergebnisse basieren...

TAMPERE, Finlandia--(BUSINESS WIRE)--Una ricerca sul DNA antico condotta dal Centro museale Vapriikki di Tampere, in Finlandia, in collaborazione con le università di Turku e Helsinki, ha fornito nuovi dati preziosi su parentela, salute e continuità della popolazione nella Finlandia medievale e della prima età moderna. I risultati della ricerca, pubblicati sulla rivista scientifica iScience dopo essere stati sottoposti a peer review, sono stati ottenuti dai resti di 25 persone in Finlandia – un...

TAMPERE, Finland--(BUSINESS WIRE)--Onderzoek naar oud DNA, geleid door het Museum Centre Vapriikki in Tampere, Finland, in samenwerking met de universiteiten van Turku en Helsinki, heeft nieuwe inzichten opgeleverd in verwantschap, gezondheid en bevolkingscontinuïteit in middeleeuws en vroegmodern Finland. Het onderzoek, gepubliceerd in het peer-reviewed tijdschrift iScience, presenteert de resultaten van 25 personen in Finland – een significant resultaat in een land waar zure bodems vaak leide...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer’s disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, for patients being evaluated for cognitive complaints through a simpl...

TAMPERE, Finlande--(BUSINESS WIRE)--Des recherches sur l’ADN ancien menées par le Centre de musées Vapriikki à Tampere, en Finlande, en collaboration avec les universités de Turku et d’Helsinki, ont permis d’obtenir de nouvelles informations sur la parenté, la santé et la continuité démographique en Finlande médiévale et au début de l’époque moderne. Publiée dans la revue scientifique iScience, cette étude présente des données obtenues à partir de 25 individus en Finlande, ce qui constitue un r...